Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 5/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1918728 | 0.82 | KMT2A (0.49) | CYP2C9CYP2C19L3MBTL1ATMNPC1 | |
| SCHEMBL9537813 | 0.81 | CA12 (0.44) | CYP2C9CYP2C19CA12CA9L3MBTL1 | |
| SCHEMBL6256304 | 0.81 | GAA (0.50) | CYP2C9CYP2C19CA12CA9L3MBTL1 | |
| SCHEMBL30569442 | 0.78 | NR1H4 (0.46) | L3MBTL1ATMNPC1KDM4EUSP2 | |
| SCHEMBL1398779 | 0.77 | CYP2C19 (0.63) | CYP2C9CYP2C19L3MBTL1KDM4EUSP2 | |
| SCHEMBL454618 | 0.76 | CA12 (0.78) | CYP2C9CA12CA9KDM4EABCG2 | |
| SCHEMBL15864329 | 0.75 | KDM4E (0.64) | CYP2C9CYP2C19CA12CA9L3MBTL1 | |
| SCHEMBL10603665 | 0.74 | KDM4E (0.49) | CYP2C19CA12CA9L3MBTL1NPC1 | |
| SCHEMBL11813859 | 0.74 | KDM4E (0.49) | CYP2C9CYP2C19CA12CA9L3MBTL1 | |
| SCHEMBL1520307 | 0.74 | KMT2A (0.50) | CYP2C19NPC1KDM4EUSP2CSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666863-B2 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090281336-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | SAHA ASHIS K | 2009-11-12 | — | — | US | disclosed |
| US-20070231318-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | SAHA ASHIS K | 2007-10-04 | — | — | US | disclosed |
| US-7265152-B2 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070231318-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | BBOX1, HAVCR2, CYP2E1 | CYP2C9 129/4885CYP2C19 117/4885CA12 3749/4885 |
| US-20090281336-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | BBOX1, HAVCR2, CYP2E1 | CYP2C9 129/4885CYP2C19 117/4885CA12 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.